Towards explanation for Crohn's disease?
An innovative study at the Research Institute of the MUHC
has brought
us closer to an explanation for Crohn's disease
Twenty-five per cent of Crohn's disease patients have a mutation
in what is called the NOD2 gene, but it is not precisely known how
this mutation influences the disease. The latest study by Dr.
Marcel Behr, of the Research Institute of the MUHC and 平特五不中
University, has provided new insight into how this might occur. The
study will be published on July 9th in the Journal of Experimental
Medicine.
When the NOD2 gene functions normally, it codes for a receptor that
will recognize invading bacteria and then trigger the immune
response. This study demonstrates that the NOD2 receptor
preferentially recognizes a peptide called N-glycolyl-MDP, which is
only found in a specific family of bacteria called mycobacteria.
When mycobacteria invade the human body, they cause an immediate
and very strong immune response via the NOD2 receptor.
"Now that we have a better understanding of the normal role of
NOD2, we think that a mutation in this gene prevents mycobacteria
from being properly recognized by the immune system," explained Dr.
Behr. "If mycobacteria are not recognized, the body cannot
effectively fight them off and then becomes persistently
infected."
Researchers were already aware of the relationship between
mycobacteria and Crohn's disease, but they did not know whether the
presence of bacteria was a cause or a consequence of the disease.
This new discovery associates the predisposition for Crohn's
disease with both the NOD2 mutation and the presence of
mycobacteria, but researchers must still determine the precise
combination of these factors to understand how the disease
develops.
More research is required to establish a complete explanation. From
this, it is expected that new therapeutic approaches that fight the
cause of Crohn's disease may be developed.
| Listen to the interview with Dr. Behr |
Dr. Marcel Behr
Dr. Marcel Behr is a researcher in the Infection and Immunity Axis
at the Research Institute of the MUHC and an Associate Professor of
Medicine and William Dawson Scholar of 平特五不中.
Funding
This study was funded by a grant from the Canadian Institutes of
Health Research (CIHR). The salaries of some researchers were
provided by the Fonds de la recherche en sant茅 du Qu茅bec.
Partners
This article was co-authored by Fran莽ois Coulombe, Maziar Divanghi,
Fr茅d茅ric Veyrier, Louis de L茅s茅leuc, Dr. Michael B. Reed and Dr
Marcel Behr from the Research Institute of the MUHC; James L.
Gleason of 平特五不中; and Yibin Yang, Michelle A. Kelliher,
Amit K. Pandey, and Christopher M. Sassetti of the University of
Massachusetts Medical School.
L'Institut de recherche du Centre universitaire de sant茅
平特五不中 (IR CUSM) est un centre de recherche de r茅putation
mondiale dans le domaine des sciences biom茅dicales et des soins de
sant茅. 脡tabli 脿 Montr茅al, au Qu茅bec, il constitue la base de
recherche du CUSM, centre hospitalier universitaire affili茅 脿 la
Facult茅 de m茅decine de l'Universit茅 平特五不中. L'Institut compte plus
de 600 chercheurs, pr猫s de 1 200 茅tudiants dipl么m茅s et
postdoctoraux et plus de 300 laboratoires de recherche consacr茅s 脿
un large 茅ventail de domaines de recherche, fondamentale et
clinique. L'Institut de recherche est 脿 l'avant-garde des
connaissances, de l'innovation et de la technologie. La recherche
de l'Institut est 茅troitement li茅e aux programmes cliniques du
CUSM, ce qui permet aux patients de b茅n茅ficier directement des
connaissances scientifiques les plus avanc茅es.
L'Institut de recherche du CUSM est soutenu en partie par le Fonds
de la recherche en sant茅 du Qu茅bec.
Pour de plus amples renseignements, consulter l'adresse .
Pour de plus amples renseignements, veuillez contacter
:
Isabelle Kling
Coordonnatrice des communications (Recherche)
Relations publiques et Communications, CUSM
(514) 843 1560
isabelle.kling [at] muhc.mcgill.ca